Drugs / PRGN-2009
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04432597 | Aug 2020 → Nov 2022 overdue | anal carcinoma, cervical cancer, oropharynx cancer, virus associated tumor | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06157151 | Nov 2025 → Nov 2026 expected | cervical carcinoma, virus associated tumor | Precigen, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT06223568 | Jun 2024 → Jan 2028 expected | head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma, oropharynx cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05996523 | Nov 2023 → May 2025 overdue | oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRGN-2009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06223568 ↗ |
| Modality | Vaccine | “PRGN-2009 is an anti-HPV immunotherapeutic vaccine.” NCT05996523 ↗ |
| Route | Subcutaneous | “HPV vaccine injected under the skin” NCT04432597 ↗ |